PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsFDA approves breast cancer recurrence test

BioNews

FDA approves breast cancer recurrence test

Published 16 February 2007 posted in News and appears in BioNews 395

Author

Zulehkha Waheed

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

The US Food and Drug Administration (FDA) has approved a genetic test that can give women with breast cancer an estimate of whether the disease is likely to return within five to ten years. The MammaPrint test - made by Dutch company Agendia - relies on an intricate computer...

The US Food and Drug Administration (FDA) has approved a genetic test that can give women with breast cancer an estimate of whether the disease is likely to return within five to ten years. The MammaPrint test - made by Dutch company Agendia - relies on an intricate computer analysis, which measures the activity of 70 different genes.


Tissue from a surgically removed breast tumour is analysed to establish the activation and suppression patterns of particular genes which are likely to affect recurrence. According to the FDA, similar devices already exist but they usually only measure one or two genes. The results of this new test will provide a 'risk score' that will tell patients if they have a high or low risk of their disease returning in the next decade.
Officials believe that this test will be an important step toward personalising treatment for individual patients. However, they caution that the test is not perfect and is not a substitute for the guidance of a cancer specialist, who tailors a woman's therapy based on factors such as general health, age and tolerance for treatment. They emphasised that doctors and patients should use it in conjunction with other information to decide how aggressively to treat an early tumour.


Steve Gutman, director of FDA's Office of In Vitro Diagnostic Device Evaluation and Safety said that, 'This test is an important step in our journey toward having improved personalised molecular medicine as a tool for use in making better treatment decisions'. He also highlighted that the test is much more accurate at predicting if a woman has a low risk of recurrence. Women at high risk have double the chance of breast cancer returning and spreading than low-risk women. Low risk patients were accurately picked at least 90 per cent of the time. However, just over 20 per cent of the women who were told they were at high risk for a relapse within five years experienced a recurrence.

Sources and References

  • 07/02/2007
    Kaiser Network
    FDA Approves Genetic Test That Predicts Odds of Breast Cancer Recurrence
  • 06/07/2007
    Reuters
    US OKs test to predict Breast Cancer Return

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 January 2007 • 2 minutes read

New breast cancer risk gene identified

by Dr Jess Buxton

UK scientists have identified a gene which, when mutated, doubles the risk of breast cancer developing in women who inherit a single copy. A faulty copy of the PALB2 gene is linked to an increased lifetime risk of the disease, from around one in nine to...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 November 2006 • 2 minutes read

Moderate breast cancer risk in women with negative gene tests

by Dr Jess Buxton

Women with a family history of breast cancer who do not have mutations in the breast cancer genes BRCA1 and BRCA2 are still at increased risk of developing the disease, say UK researchers. The scientists say that women who test negative for the mutation carried...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 October 2006 • 2 minutes read

New breast cancer risk gene discovered

by Dr Jess Buxton

Researchers based at the UK's Institute of Cancer Research (ICR) have discovered that women who inherit a faulty version of a gene called BRIP1 have an increased risk of developing breast cancer. The scientists, who reported the findings at the National Cancer Research Institute conference and...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 September 2006 • 2 minutes read

FDA releases genetic test guidance

by Dr Jess Buxton

The US Food and Drug Administration (FDA) released two sets of draft guidelines relating to some types of diagnostic genetic tests last week. According to Kathy Hudson, director of the Genetics and Public Policy Center at Johns Hopkins University, the documents clarify the role of the...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Non-invasive pregnancy test shows promise

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels


easyfundraising
amazon

This month in News

  • Popular
  • Recent
20 November 2023 • 3 minutes read

HFEA publishes recommendations for reform of fertility law

13 November 2023 • 2 minutes read

Four BRCA mutation carriers undergo removal of ovaries during C-section 

13 November 2023 • 2 minutes read

Frequent mobile phone use linked to lower sperm count in young men

6 November 2023 • 3 minutes read

Health Council of the Netherlands recommends doubling the 14-day limit on embryo research

30 October 2023 • 2 minutes read

Government to scrap additional IVF screening for same-sex couples

27 November 2023 • 2 minutes read

Research into gene therapy reveals blood cancer risk

27 November 2023 • 2 minutes read

Polish Parliament debates reinstatement of state IVF funding

27 November 2023 • 2 minutes read

Over 100,000 DNA evidence samples must be re-tested in Australia

27 November 2023 • 2 minutes read

Childhood autism associated with infertility in parents

27 November 2023 • 2 minutes read

Unintended consequence of CRISPR/Cas9 genome editing discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856